Antisense oligonucleotide therapy mitigates autosomal dominant progressive hearing loss in a murine model of human DFNA2.

Moreover, the wave I amplitudes of ASO-123-treated mice in response to 6- and 12-kHz tone stimuli also showed an increasing trend when compared with those of untreated mice ( Figure S9 A), and the wave I latency of ASO-123-treated mice showed a decreasing trend compared with that of non-injected Kcnq4 W277S/+ mice ( Figure S9 B).

also in 47,180 other papers